Effects of Schedule I drug laws on neuroscience research and treatment innovation
- PMID: 23756634
- DOI: 10.1038/nrn3530
Effects of Schedule I drug laws on neuroscience research and treatment innovation
Abstract
Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses - for example, in depression and post-traumatic stress disorder - difficult and in many cases almost impossible.
Comment in
-
Controlled substances and innovation of biomedicine: a preclinical perspective.Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c1. Epub 2013 Oct 23. Nat Rev Neurosci. 2013. PMID: 24149185 No abstract available.
-
New victims of current drug laws.Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c2. Epub 2013 Oct 23. Nat Rev Neurosci. 2013. PMID: 24149187 No abstract available.
Similar articles
-
New victims of current drug laws.Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c2. Epub 2013 Oct 23. Nat Rev Neurosci. 2013. PMID: 24149187 No abstract available.
-
Controlled substances and innovation of biomedicine: a preclinical perspective.Nat Rev Neurosci. 2013 Dec;14(12):877. doi: 10.1038/nrn3530-c1. Epub 2013 Oct 23. Nat Rev Neurosci. 2013. PMID: 24149185 No abstract available.
-
New Zealand's review of the Psychoactive Substances Act 2013: a missed learning opportunity ahead of the national cannabis law reform referendum?Addiction. 2019 Jun;114(6):1129-1130. doi: 10.1111/add.14589. Epub 2019 Mar 20. Addiction. 2019. PMID: 30801839 No abstract available.
-
Evolution of Italian laws banning trafficking, use and abuse of psychotropic drugs.Ann Ist Super Sanita. 2020 Jan-Mar;56(1):76-89. doi: 10.4415/ANN_20_01_12. Ann Ist Super Sanita. 2020. PMID: 32242539 Review.
-
New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.Int J Environ Res Public Health. 2020 Nov 23;17(22):8704. doi: 10.3390/ijerph17228704. Int J Environ Res Public Health. 2020. PMID: 33238595 Free PMC article. Review.
Cited by
-
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.Sci Rep. 2024 Nov 14;14(1):28022. doi: 10.1038/s41598-024-78736-1. Sci Rep. 2024. PMID: 39543323 Free PMC article.
-
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.EClinicalMedicine. 2024 Jul 3;74:102711. doi: 10.1016/j.eclinm.2024.102711. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39050106 Free PMC article. Review.
-
The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns.Arch Toxicol. 2024 Aug;98(8):2409-2427. doi: 10.1007/s00204-024-03765-8. Epub 2024 May 14. Arch Toxicol. 2024. PMID: 38743292 Review.
-
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.Psychopharmacology (Berl). 2024 May 14. doi: 10.1007/s00213-024-06599-5. Online ahead of print. Psychopharmacology (Berl). 2024. PMID: 38743110 Review.
-
Brain dynamics predictive of response to psilocybin for treatment-resistant depression.Brain Commun. 2024 Feb 15;6(2):fcae049. doi: 10.1093/braincomms/fcae049. eCollection 2024. Brain Commun. 2024. PMID: 38515439 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources